TScan Therapeutics Names Gavin MacBeath CEO; David Southwell Becomes Executive Chair

TL;DR

**TCRX CEO David Southwell moves to Executive Chair, CSO Gavin MacBeath takes over as CEO.**

AI Summary

TScan Therapeutics, Inc. (TCRX) filed an 8-K on January 29, 2024, reporting that its President and CEO, David Southwell, will transition to a new role as Executive Chair of the Board of Directors, effective January 24, 2024. Concurrently, Dr. Gavin MacBeath, the company's Chief Scientific Officer, has been appointed as the new President and CEO. This leadership change is significant for investors as it signals a strategic shift, potentially emphasizing scientific development under Dr. MacBeath's leadership while retaining Mr. Southwell's experience at the board level.

Why It Matters

Leadership changes can significantly impact a company's strategic direction and operational execution, directly affecting its future performance and stock value.

Risk Assessment

Risk Level: medium — While the outgoing CEO remains involved as Executive Chair, any change in top leadership introduces uncertainty regarding future strategy and execution.

Analyst Insight

Investors should monitor future company announcements and earnings calls for insights into the new CEO's strategic priorities and any shifts in the company's operational focus. Evaluate how the new leadership structure impacts TScan's pipeline development and commercialization efforts.

Key Players & Entities

• David Southwell (person) — former President and CEO, now Executive Chair of the Board of Directors
• Dr. Gavin MacBeath (person) — former Chief Scientific Officer, now President and CEO
• TScan Therapeutics, Inc. (company) — the registrant
• January 24, 2024 (date) — effective date of leadership changes

Forward-Looking Statements

• TScan Therapeutics will likely increase its focus on scientific research and development initiatives under Dr. MacBeath's leadership. (TScan Therapeutics, Inc.) — medium confidence, target: 2025-01-24
• The company's strategic direction will benefit from the combined experience of Dr. MacBeath as CEO and Mr. Southwell as Executive Chair. (TScan Therapeutics, Inc.) — medium confidence, target: 2025-01-24

FAQ

From the Filing

0001193125-24-017379.txt : 20240129 0001193125-24-017379.hdr.sgml : 20240129 20240129071503 ACCESSION NUMBER: 0001193125-24-017379 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240124 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240129 DATE AS OF CHANGE: 20240129 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TScan Therapeutics, Inc. CENTRAL INDEX KEY: 0001783328 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825282075 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40603 FILM NUMBER: 24570080 BUSINESS ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 857-399-9500 MAIL ADDRESS: STREET 1: 880 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d683269d8k.htm 8-K 8-K false 0001783328 0001783328 2024-01-24 2024-01-24     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2024     TSCAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-40603   82-5282075 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   830 Winter Street , Waltham , Massachusetts   02451 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code (857) 399-9500 Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trade Symbol(s)   Name of each exchange on which registered Voting Common Stock, $0.0001 par value per share   TCRX   The Nasdaq Global Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐       Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer On January 29, 2024, TScan Therapeutics, Inc. (the “Company”) announced the appointment of Jason A. Amello as Chief Financial Officer, which was approved by the Board of Directors of the Company on January 24, 2024, effective January 29, 2024 (the “Start Date”). Effective as of his Start Date, Mr.&#